Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on September 7, 2016. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The registrant is based in Victoria, British Columbia, and files annual reports under Form 40-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a cover sheet referencing an external news release and does not contain financial statements or quantitative performance data.
Material Changes
No material changes to financial position or operations are detailed in this filing text. The document solely announces a corporate event.
Guidance, Outlook, and Management Commentary
The primary content of this filing is the announcement that Aurinia Pharmaceuticals will present at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference. No specific financial guidance, risk factors, or management commentary regarding future performance is included in the text of this Form 6-K.
Key Facts for Investor Verification
- Verify the date and agenda of the 2016 Rodman & Renshaw 18th Annual Global Investment Conference to locate the company's presentation materials.
- Review the referenced news release (Exhibit 99.1) for details on the presentation content, as the Form 6-K text itself contains no substantive data.
- Consult the company's most recent Form 40-F or quarterly reports for actual financial metrics, as this filing does not include them.